Loading...
•
Mar 31
•/
Ascendis Pharma Q1 2025 Earnings Report
Reported First Quarter 2025 Financial Results
Key Takeaways
Ascendis Pharma reported a net loss of €94.6 million for the first quarter of 2025, an improvement from the €131.0 million net loss in the same period of 2024. Total revenue increased to €101.0 million, driven by strong product revenue from SKYTROFA and the commercial launch of YORVIPATH. The company ended the quarter with €518 million in cash and cash equivalents.
Total revenue for Q1 2025 was €101.0 million, up from €95.9 million in Q1 2024.
Net loss for Q1 2025 was €94.6 million, compared to a net loss of €131.0 million in Q1 2024.
SKYTROFA generated €51.3 million in revenue and YORVIPATH generated €44.7 million in revenue in Q1 2025.
Cash and cash equivalents totaled €518 million as of March 31, 2025.
Ascendis Pharma
Ascendis Pharma
Ascendis Pharma Revenue by Segment
Revenue by Segment
Commercial Products Revenue
CapyFin.comRendering of Services & Clinical Supply Revenue
CapyFin.comLicenses Revenue
CapyFin.comSKYTROFA Revenue
CapyFin.comYORVIPATH Revenue
CapyFin.com Forward Guidance
Ascendis Pharma anticipates potential approvals for TransCon CNP as a monotherapy in children with achondroplasia and expects topline data from the COACH trial in Q2 2025. They plan commercial launches for YORVIPATH in additional European countries and submissions for TransCon hGH and TransCon CNP in various indications.
Positive Outlook
- Potential approvals for TransCon CNP as monotherapy.
- Upcoming topline COACH combination trial data.
- On track for commercial launch of YORVIPATH in additional Europe Direct countries.
- Planned IND/similar submissions for TransCon hGH in additional indications.
- Planned IND/similar submissions for TransCon CNP alone or in combination for hypochondroplasia.
Challenges Ahead
- Dependence on third party manufacturers, distributors and service providers.
- Unforeseen safety or efficacy results in development programs or on-market products.
- Unforeseen expenses related to commercialization and development programs.
- Delays in development programs due to various factors.
- Ability to obtain additional funding.
Revenue & Expenses
Visualization of income flow from segment revenue to net income